The Hamburg-based company Indivumed has repositioned itself, sending a clear message with a recent change in leadership: A new chapter is beginning with the focus on discovering and developing novel therapeutic targets for innovative cancer therapies. |transkript spoke with Prof. Dr. Hartmut Juhl and Dr. Matthias Evers.
ADVERTISEMENT